Skip to main content
MediWound Ltd. logo

MediWound Ltd. — Investor Relations & Filings

Ticker · MDWD ISIN · IL0011316309 LEI · 549300LJKCS74GRYKF90 US Manufacturing
Open in API
Filings indexed 370 across all filing types
Latest filing 2023-02-08 Major Shareholding Noti…
Country IL Israel
Listing US MDWD

About MediWound Ltd.

https://www.mediwound.com/

MediWound Ltd. is a fully integrated biopharmaceutical company that develops, manufactures, and commercializes enzymatic therapeutics for non-surgical tissue repair. The company's core technology focuses on next-generation treatments that selectively remove eschar (non-viable tissue) from severe burns and chronic wounds while preserving healthy tissue. This approach is designed to accelerate healing, improve patient outcomes, and lower overall healthcare costs. Its primary commercial product is a topical biologic for the debridement of severe thermal burns. MediWound maintains a research and development pipeline aimed at expanding its enzymatic platform to address additional unmet medical needs in wound care.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G
Major Shareholding Notification
2023-02-08 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, MediWound Ltd., reporting on a securities purchase agreement and the closing of an offering of ordinary shares. It includes details about the offering, proceeds, use of funds, and related legal opinions and press releases. The content focuses on a capital raising event and financing activities. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a simple announcement of a report publication but a substantive filing about financing. Therefore, the document fits best under Capital/Financing Update (CAP).
2023-02-07 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus for an offering of ordinary shares by MediWound Ltd. It includes detailed information about the share offering, pricing, use of proceeds, risk factors, and legal matters. The document is filed pursuant to Rule 424(b)(5), which relates to prospectus supplements for securities offerings. This type of document is related to capital raising activities and financing updates rather than financial reports, management discussions, or regulatory filings unrelated to financing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, supporting a high confidence level.
2023-02-03 English
424B3
Investor Presentation Classification · 95% confidence The document is a Form 6-K filed by MediWound Ltd. It includes a prospectus supplement and a presentation made at the J.P. Morgan 41st Annual Healthcare Conference. The presentation discusses clinical products, clinical trial results, financial estimates, and company strategy. The document explicitly states that the presentation materials are furnished as Exhibit 99.1 to the Form 6-K and are available on the company's website. The Form 6-K is a report of a foreign private issuer used to furnish information to the SEC that is not required to be filed on Forms 20-F or 40-F. The content is primarily a presentation for investors focusing on financials, strategy, and market position, typical of an Investor Presentation. The document is not an annual or quarterly report, audit report, earnings release, or other regulatory filing types. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-01-09 English
6-K
Investor Presentation Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a presentation made at the J.P. Morgan 41st Annual Healthcare Conference, including clinical product updates and financial projections. The document is relatively short (3169 characters) and primarily serves to furnish the presentation materials rather than provide a full financial report. The presentation is described as an investor-focused update on strategy and market position. Therefore, this document fits best as an Investor Presentation (IP) rather than an Annual Report, Earnings Release, or Regulatory Filing. The presence of the presentation as Exhibit 99.1 and the context of a healthcare conference further support this classification.
2023-01-09 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by MediWound Ltd., which is a report of a foreign private issuer filed pursuant to the Securities Exchange Act of 1934. It includes a press release announcing FDA approval of a product (NexoBrid) and related milestone payments. The document is not a full financial report, annual or interim, nor is it an earnings release or management discussion. It is a regulatory filing that provides material company news and updates but does not contain detailed financial statements or comprehensive financial analysis. The document length is about 15,000 characters, which is typical for a Form 6-K containing a press release and explanatory notes. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-01-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.